New weight loss pill outperforms Wegovy in early trials

12 Sept 2024


Novo Nordisk's new obesity pill, amycretin, has shown promising results in early clinical trials, with participants losing up to 13% of their body weight in just 12 weeks, significantly outperforming placebo groups. The treatment may offer faster weight loss than Novo's popular Wegovy injection.

Forbes